The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NTRA | +54.08% | +177.39% | +22.64% | +729% |
| S&P | +14.84% | +96.04% | +14.41% | +224% |
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The firm also offers Constellation, a cloud-based software product that allows laboratory customers to gain access to the algorithms and bioinformatics in order to validate and launch tests based on the technology. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $546.60M | 32.2% |
| Gross Profit | $346.60M | 42.5% |
| Gross Margin | 63.41% | 4.6% |
| Market Cap | $23.07B | 73.5% |
| Market Cap / Employee | $5.20M | 0.0% |
| Employees | 4.4K | 34.6% |
| Net Income | -$100.94M | -169.4% |
| EBITDA | -$100.51M | -179.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.00B | 25.5% |
| Accounts Receivable | $309.22M | -8.0% |
| Inventory | 54.3 | 32.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $102.74M | -70.2% |
| Short Term Debt | $93.39M | 0.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -15.47% | 5.7% |
| Return On Invested Capital | -37.00% | 3.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $11.68M | 251.9% |
| Operating Free Cash Flow | $37.57M | 841.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.94 | 22.37 | 15.69 | 18.52 | 11.13% |
| Price to Sales | 10.26 | 12.26 | 10.41 | 11.73 | 19.96% |
| Price to Tangible Book Value | 17.94 | 22.37 | 15.69 | 18.52 | 11.13% |
| Price to Free Cash Flow TTM | 300.41 | 223.67 | 220.37 | - | |
| Enterprise Value to EBITDA | -490.29 | -351.53 | -261.07 | -221.08 | -38.11% |
| Free Cash Flow Yield | 0.3% | 0.4% | 0.5% | - | |
| Return on Equity | -25.8% | -19.4% | -18.7% | -24.3% | -40.37% |
| Total Debt | $475.73M | $187.12M | $195.60M | $196.14M | -55.18% |
NTRA earnings call for the period ending September 30, 2021.
NTRA earnings call for the period ending March 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
